DigmBio
June 24, 2026
Theater 2
Type: Company Presentation
Focus Area:
Oncology
DigmBio: Next-Generation Small-Molecule Therapeutics
* DigmBio: Advancing High-Selectivity & Superior BBB-Penetrating Therapies for Oncology and CNS
* Established: April 2020 (Bio-startup)
* Mission: Developing First-in-Class therapies by overcoming the safety and delivery (BBB) limitations of existing drugs.
* Major Assets: DM5167 (2nd-Generation BBB-penetrating PARP-1 Selective Inhibitor) at clinical stage; DM3159 and DM3190 (TASR-Targeting Neurogenesis and Neuroprotection) at IND-enabling stage
Company HQ City:
Seongnam-si
Company HQ State:
Gyeonggi-do
Company HQ Country:
Korea, Republic of
Year Founded:
2020
Lead Product in Development:
DM5167 (oncology, Phase ib ongoing)
DM3159/3190 (CNS, GLP-Tox in preparation)
CEO
Jeongmin KIM (CEO)
Jung-Ho KIM (CSO)
George Nam (CBO)
Development Phase of Lead Product
Phase I
When you expect your next catalyst update?
1H of 2027
What is your next catalyst (value inflection) update?
Phase 1b expansion study results of DM5167 in metastatic bran cancer and PARP inhibitor naive patients, respectively
Primary Speaker
)
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}